Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.90 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515442 | 0.95 | CNR2 (1.00) | CNR2CNR1ABCB11CYP1A2CYP3A4 | |
| SCHEMBL15516390 | 0.90 | CNR2 (1.00) | CNR2CNR1GAA | |
| SCHEMBL17694503 | 0.88 | CNR2 (0.90) | CNR2CNR1GAASTING1 | |
| SCHEMBL15506433 | 0.83 | CNR2 (1.00) | CNR2CNR1GAASTING1 | |
| SCHEMBL15515752 | 0.81 | CNR2 (1.00) | CNR2CNR1ABCB11CYP1A2CYP3A4 | |
| SCHEMBL15506435 | 0.79 | CNR2 (1.00) | CNR2CNR1GAA | |
| SCHEMBL17694501 | 0.77 | CNR2 (0.73) | CNR2CNR1CYP1A2 | |
| SCHEMBL17694499 | 0.77 | CNR2 (0.63) | CNR2CYP1A2STING1L3MBTL1 | |
| SCHEMBL15506129 | 0.76 | CNR2 (0.66) | CNR2CYP1A2STING1L3MBTL1 | |
| SCHEMBL603802 | 0.74 | CNR2 (0.62) | CNR2GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108016-A1 | Novel Cannabinergic Compounds and Uses Thereof | NORTHEASTERN UNIVERSITY (US) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108016-A1 | Novel Cannabinergic Compounds and Uses Thereof | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885ABCB11 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.